Navigation Links
Inovio Pharmaceuticals to Present at American Society of Gene & Cell Therapy Annual Meeting May 18 - 21, 2011
Date:5/17/2011

an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, our ability to successfully integrate Inovio and VGX Pharmaceuticals, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2010, our Form 10-Q for the three months ended March 31, 2011, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

(Logo:  

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Inovio Pharmaceuticals Closes $24.3 Million Registered Offering
2. University of Southampton and Inovio Pharmaceuticals Initiate Phase 2 Clinical Study to Evaluate Leukemia DNA Vaccine Using Electroporation Delivery Technology
3. Inovio Pharmaceuticals Dual-Antigen SynCon™ DNA Vaccine for Prostate Cancer Induces Robust Responses in Preclinical Trial
4. Inovio Pharmaceuticals Unveils Needle-free, Contactless Electroporation Technology for DNA Vaccine Delivery
5. Inovio Pharmaceuticals to Present at Partnering and Scientific Conferences
6. Inovio Pharmaceuticals to Present at Cowen & Co. Health Care Conference
7. Inovio Pharmaceuticals to Present at ROTH 23rd Annual Growth Stock Conference
8. Inovio Pharmaceuticals Partner ChronTech Initiates Phase II Clinical Trial of Hepatitis C Virus DNA Vaccine Using Inovios Electroporation Delivery Technology
9. OncoSec Medical Licenses Non-DNA Vaccine Tumor Therapy Technology from Inovio Pharmaceuticals
10. Inovio Pharmaceuticals Licenses Non-DNA Vaccine Tumor Therapy Technology to OncoSec Medical
11. Inovio Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... SAN DIEGO , Aug. 29, 2014 /PRNewswire/ ... an emerging biopharmaceutical company, announced today that Santosh ... will be leaving the Company, for personal reasons, ... the Chief Medical Officer of Aires Pharmaceuticals, which ... Vetticaden,s former responsibilities as the Company,s interim Chief ...
(Date:8/29/2014)... 2014 Thoratec Corporation (NASDAQ: THOR ... therapies to save, support and restore failing hearts, said ... Stanley Global Healthcare Conference on Wednesday, September 10. ... Executive Officer, will provide an update on the company, ... Pacific Daylight Time).   A webcast of ...
(Date:8/29/2014)... 29, 2014 Research and Markets ... Instrument Industry Report, 2014-2017" report to their offering. ... rising proportion of reimbursement for medical expenses, the Chinese ... its scale presenting a CAGR of 19.2% during 2009-2013. ... product segments of orthopedic instruments in China ...
Breaking Medicine Technology:Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4China Orthopedic Instrument Industry Report, 2014-2017 2
... and WALTHAM, Mass., May 25, 2011 Interleukin Genetics, Inc. ... USP Hospitales now offers the innovative Heart Health Genetic ... Hospitales, the flagship hospital in Madrid, and will soon ... identifies single nucleotide variations in two Interleukin-1 (IL-1) genes ...
... May 25, 2011 Cambridge Temperature Concepts (CTC), ... has been awarded an I Award by the Wireless-Life ... to solving healthcare challenges . DuoFertility uses wireless technology to ... a baby the best possible chance of conceiving naturally. News ...
Cached Medicine Technology:USP Hospitales of Spain to Offer Interleukin Genetics' Heart Health Test Throughout Its Hospital Network 2USP Hospitales of Spain to Offer Interleukin Genetics' Heart Health Test Throughout Its Hospital Network 3USP Hospitales of Spain to Offer Interleukin Genetics' Heart Health Test Throughout Its Hospital Network 4Cambridge Temperature Concepts Wins Prestigious Award From the Wireless-Life Sciences Alliance for Fertility Monitor DuoFertility 2Cambridge Temperature Concepts Wins Prestigious Award From the Wireless-Life Sciences Alliance for Fertility Monitor DuoFertility 3Cambridge Temperature Concepts Wins Prestigious Award From the Wireless-Life Sciences Alliance for Fertility Monitor DuoFertility 4
(Date:8/29/2014)... Angeles, CA (PRWEB) August 29, 2014 ... inspired others who talked about introducing these cutting ... experience as chairman of the FUE Research Committee has ... studies that redefine what is possible with modern technology. ... of a variety of FUE devices that facilitate extraction ...
(Date:8/29/2014)... 2014 According to a CNN article, ... (8/25), a new study found that those states ... seen a significant decrease in the number of painkiller ... ten year period, and comparing various states with and ... that there was about a 25% decrease in painkiller ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 As reported by ... Monitoring For Drug Abuse Trends , Outbreaks (8/20), the National ... attempt to monitor drug abuse trends by turning to social ... drug abuse trends, it is also working with the University ... National Drug Early Warning System, which will be funded by ...
(Date:8/29/2014)... An article entitled How Genes, Gender and ... explains how genes, gender and the environment that an individual ... drugs. Researchers at Indiana University are taking another look at ... and are applying this factor to what is known about ... family and community ties can help to reduce a man’s ...
(Date:8/29/2014)... 29, 2014 Healthpointe is proud to ... Dr. Rodas will be practicing out of Healthpointe’s newest ... member of Healthpointe’s orthopedic team, Dr. Rodas ... and board-certified in occupational medicine. , Among Dr. ... Medical Director of Raytheon, the world-class defense and aerospace ...
Breaking Medicine News(10 mins):Health News:Parsa Mohebi M.D., Beverly Hills Hair Restoration Surgeon Gives Inspiring Lecture on Groundbreaking Techniques in Follicular Unit Extraction 2Health News:Overdoses on Painkillers Decreased in States With Medical Marijuana 2Health News:Overdoses on Painkillers Decreased in States With Medical Marijuana 3Health News:Social Media Proves to Be Helpful in Fighting Drug Abuse 2Health News:Social Media Proves to Be Helpful in Fighting Drug Abuse 3Health News:Substance Abuse Likelihood Affected by Environment, Gender and Genes 2Health News:Substance Abuse Likelihood Affected by Environment, Gender and Genes 3Health News:Dr. Anthony G. Rodas Joins Healthpointe Team at LAX Office 2
... in necessary prescriptions, study finds , , TUESDAY, Feb. 3 ... "doughnut hole" in the Medicare Part D drug plan ... with an employer-based plan, a new study finds. , ... costs from hospitalizations and doctor visits resulting from this ...
... Ala. Exposure to second-hand smoke and alcohol significantly ... at the University of Alabama at Birmingham (UAB). , ... and alcohol are worse for health as a combination, ... an associate professor in the UAB Department of Environmental ...
... Group, Inc.,(NYSE Alternext US: QGP) ( www.QuantumMD.com ) announced ... debut at the 2009 Pri-Med,South Conference and Expo alongside ... Quantum believes PWeR is the next generation in healthcare ... Obama is calling for within,the industry. Pete Martinez, ...
... A thesis from the Sahlgrenska Academy, University of Gothenburg, ... suicide attempt are five times more likely to attempt ... nightmares. , The study included 165 patients aged ... psychiatric departments following a suicide attempt in Sweden. Psychiatric ...
... Feb. 3 Physicians have been raving about the ... 2008 survey of U.S. VASER Lipo physicians, 95% of ... physician or facility. The VASER Lipo System ... contouring applications from precise sculpting to significant fat removal."Hundreds ...
... improve writing skills for those with aphasia with the aid ... doctoral thesis from the Sahlgrenska Academy at the University of ... use spoken language, and the ability to read and write. ... writing aids in the study on which speech and language ...
Cached Medicine News:Health News:Medicare Drug Plan 'Doughnut Hole' Could Impact Seniors' Health 2Health News:Tobacco smoke and alcohol harm liver worse as combo 2Health News:PWeR(TM) Introduced at Regional Healthcare Conference 2Health News:PWeR(TM) Introduced at Regional Healthcare Conference 3Health News:PWeR(TM) Introduced at Regional Healthcare Conference 4Health News:Nightmares increase risk of further suicide attempts 2Health News:THE RESULTS ARE IN! VASER(R) Lipo Receives 95% Approval Rating by Physician Users 2Health News:Computerized writing aids make writing easier for persons with aphasia 2
... segment surgical procedures. For dissection of vitreoretinal ... luer lock tubing set is attached to ... - .02in (.50mm); OD - .06in (1.5mm) ... viscoelastic fluids. 30G (.30mm) tip, flattened. Angled ...
Product designed specifically for posteror segment surgical procedures. Facilitates posterior segment infusion. Flexible tubing 10in (25cm)....
For surgical treatment, repair and irrigation of the nasolacrimal system. Silicone tubing. Length 14in (35cm) ID: .012in (.30mm) OD: .025in (.60mm)...
...
Medicine Products: